v3.26.1
Product and Geographic Information (Tables)
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Sales of Company's Products
Revenues of the Company’s products were as follows:
Three Months Ended March 31,
20262025
($ in millions)U.S.Int’lTotalU.S.Int’lTotal
Women’s Health
Nexplanon/Implanon NXT$127 $74 $201 $176 $72 $248 
Follistim AQ21 39 61 35 34 69 
NuvaRing
18 24 16 22 
Ganirelix Acetate Injection
24 26 23 27 
Marvelon/Mercilon
— 26 26 — 39 39 
Jada— 15 — 15 
Other Women’s Health (1)
17 30 46 15 27 43 
General Medicines
Biosimilars
Renflexis42 15 57 44 12 57 
Hadlima51 16 67 33 14 47 
Ontruzant14 18 
Brenzys— 20 20 — 14 14 
Other Biosimilars (1)
11 13 24 — 
Established Brands
Cardiovascular
Atozet— 85 85 — 77 77 
Zetia86 87 84 85 
Cozaar/Hyzaar55 57 53 55 
Vytorin20 21 22 23 
Rosuzet— — 
Other Cardiovascular (1)
27 28 — 30 30 
Respiratory
Singulair38 40 72 74 
Nasonex— 65 65 — 71 72 
Dulera23 12 35 34 10 43 
Clarinex30 31 — 34 34 
Other Respiratory (1)
11 12 10 13 
Non-Opioid Pain, Bone and Dermatology
Arcoxia— 59 59 — 62 62 
Fosamax— 29 29 32 33 
Diprospan— 35 35 — 30 30 
Vtama
23 25 20 24 
Other Non-Opioid Pain, Bone and Dermatology (1)
65 68 65 68 
Other
Propecia28 30 24 26 
Emgality— 54 54 — 32 32 
Proscar— 26 26 — 24 24 
Other (1)
85 87 76 78 
Other (2)
— 18 18 — 22 22 
Revenues$358 $1,102 $1,460 $412 $1,101 $1,513 
Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies.

(1) Includes sales of products not listed separately.
(2) Includes manufacturing sales to third parties.
Schedule of Consolidated Revenues by Geographic Area
Revenues by geographic area where derived are as follows:
Three Months Ended
March 31,
($ in millions)20262025
Europe and Canada$412 $376 
United States358 412 
Asia Pacific and Japan226 251 
China194 204 
Latin America, Middle East, Russia, and Africa
247 240 
Other (1)
23 30 
Revenues$1,460 $1,513 
(1) Includes manufacturing sales to third parties.